Adherium (ASX:ADR) announced a data-based initiative with Summatix to allow clinicians to improve care of patients with asthma and chronic obstructive pulmonary disease across the world.
New Zealand-based Adherium and Australia-based Summatix plan to build upon an existing relationship, as the former will gain access to Summatix’s platform to release data from its Hailie sensors for clinical and other relevant use. That platform allows for connected external and implanted medical device integration and shares the resulting data with patients, clinicians, payers and the device manufacturer.
The Hailie sensors, formerly known as Smartinhalers, launched in the U.S. last year. The device attaches to asthma or COPD devices to track dose compliance and promote a high level of adherence.
Adherium and Summatix plan to use their partnership to accelerate the Hailie reimbursement-focused rollout in the U.S. and other markets.
“Adherium is excited to be partnering with Summatix in our continued efforts to deliver transformative asthma/COPD patient care,” Adherium CEO Jeremy Curnock Cook said in prepared remarks. “We are confident that when combined with the Summatix platform capabilities, Adherium’s Hailie solution will deliver significant advantages for patients, caregivers, doctors, and other health care providers in managing these costly diseases.”
